<code id='42582EDC43'></code><style id='42582EDC43'></style>
    • <acronym id='42582EDC43'></acronym>
      <center id='42582EDC43'><center id='42582EDC43'><tfoot id='42582EDC43'></tfoot></center><abbr id='42582EDC43'><dir id='42582EDC43'><tfoot id='42582EDC43'></tfoot><noframes id='42582EDC43'>

    • <optgroup id='42582EDC43'><strike id='42582EDC43'><sup id='42582EDC43'></sup></strike><code id='42582EDC43'></code></optgroup>
        1. <b id='42582EDC43'><label id='42582EDC43'><select id='42582EDC43'><dt id='42582EDC43'><span id='42582EDC43'></span></dt></select></label></b><u id='42582EDC43'></u>
          <i id='42582EDC43'><strike id='42582EDC43'><tt id='42582EDC43'><pre id='42582EDC43'></pre></tt></strike></i>

          
          WSS
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive